Home Medicine Evaluation of the immature myeloid information (IMI) by Sysmex XE 2100® hematology analyzer in the identification of blasts of myeloid lineage
Article
Licensed
Unlicensed Requires Authentication

Evaluation of the immature myeloid information (IMI) by Sysmex XE 2100® hematology analyzer in the identification of blasts of myeloid lineage

  • Mariela Granero Farias EMAIL logo , Mariana Pires Garcia and Claudia Rosa Cagliari
Published/Copyright: May 3, 2012

Abstract

The immature myeloid information (IMI) provided by the Sysmex XE 2100 hematology analyzer has demonstrated that it is possible to differentiate granulocytes of immature cells in daily practice. A specific reagent lyses mature white blood cells, allowing that immature myeloid cells remain intact and consequently detectable. It is known that lymphoblasts cannot be detected in this channel. This channel does not entail additional costs, since it is provided by the traditional hematology analyzers used in blood tests and is widely useful in differentiating cell lines. This study has aimed to assess the consonance between IMI results and subtypes of acute leukemias and other hematologic malignancies in order to use it as screening test in the definition of cell lineage. A total of 141 cases of hematologic malignancies have been evaluated. Results of the IMI channel were compared using the Sudan Black cytochemical and flow cytometry. The Cohen’s Kappa coefficient of agreement between IMI and flow cytometry results was 0.8%. IMI had sensibility and specificity levels of 90.7% and 90.8%, respectively; VP: 68 (91.9%); FP: 6 (8.1%); VN: 59 (89.4%) and FN: 7 (10.6%); PPV 91.9% and NPV 89.4%. The Sysmex XE 2100 analyzer showed a good analytical performance for the detection of immature myeloid cells. These results indicate that the IMI channel has sensitivity and specificity levels, consistent with previous studies. Given this situation, one may conclude that IMI was able to be used as a screening test to complement cytochemistry for identify blasts of myeloid lineage.


Corresponding author: Mariela Granero Farias, Serviço de Patologia Clínica, Unidade de Hematologia, Hospital de Clínicas de Porto Alegre, Ramiro Barcelos, 2350, 90035-903 Porto Alegre/RS, Brazil Phone: +55 5133598674

Received: 2012-2-2
Accepted: 2012-3-30
Published Online: 2012-05-03
Published in Print: 2012-10-01

©2012 by Walter de Gruyter Berlin Boston

Articles in the same Issue

  1. Masthead
  2. Masthead
  3. Editorials
  4. Cancer epigenomics: moving slowly, but at a steady pace from laboratory bench to clinical practice
  5. Laboratory networking and sample quality: a still relevant issue for patient safety
  6. Reviews
  7. DNA methylation biomarkers and their utility for solid cancer diagnostics
  8. DNA methylation biomarkers in biological fluids for early detection of respiratory tract cancer
  9. Global DNA hypomethylation in cancer: review of validated methods and clinical significance
  10. Genetics and Molecular Diagnostics
  11. δ0-Thalassemia in cis of βKnossos globin gene: first homozygous description in thalassemia intermedia Libyans and first combination with codon 39 (C→T) in thalassemia intermedia Tunisian patients
  12. Genetic-based reference values for angiotensin-converting enzyme (ACE) according to I/D polymorphism in a Spanish population sample
  13. General Clinical Chemistry and Laboratory Medicine
  14. Effects of sample transportation on commonly requested laboratory tests
  15. Long-term (in)stability of folate and vitamin B12 in human serum
  16. Information comparison of the effects of drugs on laboratory tests in drug labels and Young’s book
  17. First evaluation of Capillarys 2 Flex Piercing® (Sebia) as a new analyzer for HbA1c assay by capillary electrophoresis
  18. Antioxidant and oligonutrient status, distribution of amino acids, muscle damage, inflammation, and evaluation of renal function in elite rugby players
  19. Validation of the body fluid module on the new Sysmex XN-1000 for counting blood cells in cerebrospinal fluid and other body fluids
  20. Measuring Rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation
  21. Cancer Diagnostics
  22. Increased concentrations of growth factors and activation of the EGFR system in breast cancer
  23. Infectious Diseases
  24. Incidence and significance of elevated lactate in the identification of critically ill patients
  25. Cardiovascular Diseases
  26. Lipoprotein-associated phospholipase A2 is elevated in patients with severe aortic valve stenosis without clinically overt atherosclerosis
  27. Diabetes
  28. Serum cystatin C as a marker for early detection of chronic kidney disease and grade 2 nephropathy in Japanese patients with type 2 diabetes
  29. Letters to the Editor
  30. Establishing professional phlebotomist group for quality control of the preanalytic variables of clinical laboratory
  31. Application of quality specification based on biological variation in planning quality control strategy
  32. Analytical and clinical evaluation of a new immunoassay for therapeutic drug monitoring of infliximab and adalimumab
  33. Comparison of relationships between FT4 and log TSH in Access DXI 800 Unicel, Modular E170 and ADVIA Centaur XP Analyzer
  34. Assay-specific pitfalls of catecholamine HPLC assays
  35. Evaluation of automated nucleated red blood cells counting on Sysmex XE5000 and Siemens ADVIA 2120
  36. Evaluation of the immature myeloid information (IMI) by Sysmex XE 2100® hematology analyzer in the identification of blasts of myeloid lineage
  37. Congress Abstracts
  38. Congress of Laboratory Medicine and Clinical Chemistry / 4th Annual Meeting of the Austrian Society for Laboratory Medicine and Clinical Chemistry (ÖGLMKC)
  39. Abstracts of the 2012 Convocation of Experts on Laboratory Quality / Embracing the Need of Continued Vigilance to Assure Quality Outcomes in the Modern Laboratory
Downloaded on 1.3.2026 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2012-0147/html
Scroll to top button